{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:25Z","timestamp":1789958845651,"version":"4.0.1"},"reference-count":154,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The advent of chimeric antigen receptor (CAR) T-cell therapy has led to dramatic remission rates in multiple relapsed\/refractory hematologic malignancies. While CAR T-cell therapy has been particularly successful as a treatment for B-cell malignancies, effectively treating acute myeloid leukemia (AML) with CARs has posed a larger challenge. AML not only creates an immunosuppressive tumor microenvironment that dampens CAR T-cell responses, but it also lacks many unique tumor-associated antigens, making leukemic-specific targeting difficult. One advantage of CAR T-cell therapy compared to alternative treatment options is the ability to provide prolonged antigen-specific immune effector and surveillance functions. Since many AML CAR targets under investigation including CD33, CD117, and CD123 are also expressed on hematopoietic stem cells, CAR T-cell therapy can lead to severe and potentially lethal myeloablation. Novel strategies to combat these issues include creation of bispecific CARs, CAR T-cell \u201csafety switches\u201d, TCR-like CARs, NK CARs, and universal CARs, but all vary in their ability to provide a sustained remission, and consolidation with an allogeneic hematopoietic cell transplantation (allo-HCT) will be necessary in most cases This review highlights the delicate balance between effectively eliminating AML blasts and leukemic stem cells, while preserving the ability for bone marrow to regenerate. The impact of CAR therapy on treatment landscape of AML and changing scope of allo-HCT is discussed. Continued advances in AML CAR therapy would be of great benefit to a disease that still has high morbidity and mortality.<\/jats:p>","DOI":"10.3390\/cancers14030497","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T21:01:51Z","timestamp":1642626111000},"page":"497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Jennifer","family":"Marvin-Peek","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Oluwole O.","family":"Olalekan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: The promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhylko, A., Winiarska, M., and Graczyk-Jarzynka, A. (2020). The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12082030"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-Cell Receptor\u2013Based Immunotherapy for Hematologic Malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2991\/chi.k.201108.001","article-title":"CART Cell Toxicities: New Insight into Mechanisms and Management","volume":"2","author":"Zahid","year":"2020","journal-title":"Clin. Hematol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tabata, R., Chi, S., Yuda, J., and Minami, Y. (2021). Emerging Immunotherapy for Acute Myeloid Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041944"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin\u2019s Lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_30","unstructured":"Cummins, K.D., Frey, N., Nelson, A.M., Schmidt, A., Luger, S., Isaacs, R.E., Lacey, S.F., Hexner, E., Melenhorst, J.J., and June, C.H. (2017). Treating Relapsed\/Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells, American Society of Hematology."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","article-title":"CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro","volume":"19","author":"Alishah","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1189\/jlb.5BT1115-524R","article-title":"At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies","volume":"100","author":"Oluwole","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.1995.6.6-813","article-title":"Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy","volume":"6","author":"Bordignon","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Tey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","article-title":"Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch","volume":"28","author":"Warda","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule\u2013gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gu, X., He, D., Li, C., Wang, H., and Yang, G. (2018). Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113455"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41375-020-01109-w","article-title":"A modular and controllable T cell therapy platform for acute myeloid leukemia","volume":"35","author":"Benmebarek","year":"2021","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.7150\/jca.28952","article-title":"Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells","volume":"10","author":"Salman","year":"2019","journal-title":"J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","article-title":"Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia","volume":"102","author":"Salih","year":"2003","journal-title":"Blood"},{"key":"ref_48","first-page":"134","article-title":"Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies","volume":"1","author":"Sahin","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.seminoncol.2019.08.005","article-title":"Significance of TIM3 expression in cancer: From biology to the clinic","volume":"46","author":"Solinas","year":"2019","journal-title":"Semin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/s41598-017-11126-y","article-title":"A TCR-based Chimeric Antigen Receptor","volume":"7","author":"Walseng","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy","volume":"16","author":"Bendle","year":"2010","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: An emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.omtm.2021.09.008","article-title":"Novel TCR-like CAR-T cells targeting an HLA\u22170201-restricted SSX2 epitope display strong activity against acute myeloid leukemia","volume":"23","author":"Raskin","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","article-title":"Aberrant marker expression patterns on the CD34+CD38\u2212 stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission","volume":"21","author":"Moshaver","year":"2007","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell\u2013associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor\u2013expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"Hughes","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells after Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Graham, C., Jozwik, A., Pepper, A., and Benjamin, R. (2018). Allogeneic CAR-T Cells: More than Ease of Access?. Cells, 7.","DOI":"10.3390\/cells7100155"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"ref_82","first-page":"3151","article-title":"From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Atilla","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.beha.2019.101104","article-title":"How close are we to CAR T-cell therapy for AML?","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"Raponi","year":"2011","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient with Relapsed and Refractory Acute Myeloid Leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Gao, X., Lin, J., Gao, L., Deng, A., Lu, X., Li, Y., Wang, L., and Yu, L. (2015). High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124241"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/\u2212CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: A Groupe Ouest-Est des Leuc\u00e9mies Aigu\u00ebs et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","article-title":"T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia","volume":"22","author":"Mardiros","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3\u2013specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-Type Lectin-Like Molecule-1","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jcmm.13519","article-title":"Mapping the CLEC 12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC 12A-related cancer stem cell biology","volume":"22","author":"Bill","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2018-99-113438","article-title":"Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fonc.2020.00685","article-title":"Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: The combination matters\u2014An analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V128.22.1072.1072","article-title":"Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"128","author":"Chien","year":"2016","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Maiorova, V., Mollaev, M.D., Vikhreva, P., Kulakovskaya, E., Pershin, D., Chudakov, D.M., Kibardin, A., Maschan, M.A., and Larin, S. (2021). Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines. Vaccines, 9.","DOI":"10.3390\/vaccines9111238"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2021-151196","article-title":"Anti-FLT3 CAR T Cells in Acute Myeloid Leukemia (Abst)","volume":"138","author":"Sleiman","year":"2021","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1479-5876-10-157","article-title":"A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4","article-title":"Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leuke-mia","volume":"85","author":"Ross","year":"1999","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e1282","DOI":"10.1002\/cti2.1282","article-title":"Mutated GM-CSF-based CAR-T cells targeting CD116\/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia","volume":"10","author":"Hasegawa","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2400794","article-title":"Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells","volume":"11","author":"Lanza","year":"1997","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2008.07491.x","article-title":"Interleukin (IL)-3\/granulocyte macrophage-colony stimulating factor\/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor","volume":"144","author":"Riccioni","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","article-title":"New strategies to treat AML: Novel insights into AML survival pathways and combination therapies","volume":"35","author":"Nair","year":"2021","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"ref_132","first-page":"6880","article-title":"Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognos-tic stratification","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood-2020-136855","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study","volume":"136","author":"Brunner","year":"2020","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","article-title":"Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","article-title":"CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease","volume":"70","author":"Lu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4103\/0366-6999.246072","article-title":"Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","volume":"131","author":"Liu","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.9","article-title":"Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML","volume":"49","author":"Anthias","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: A post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells","volume":"11","author":"You","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjh.17460","article-title":"The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy","volume":"193","author":"Dholaria","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41419-020-2388-1","article-title":"Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134472","article-title":"Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2018-99-114950","article-title":"Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood.V126.23.862.862","article-title":"Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies","volume":"126","author":"Kebriaei","year":"2015","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:04:11Z","timestamp":1760133851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":154,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030497"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030497","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}